Clinical pharmacology phase I of cefazedone, a new cephalosporin, in healthy volunteers. I. Tolerance in comparison with cefazolin.
In conjunction with pharmacokinetic investigations, the tolerance of (6R,7R)-7-(2-[3,5-dichloro-4-oxo-1 (4H)-pyridyl]-acetamido)-3-([(5-methyl-1,34-thiadiazol-2-yl)-thio]methyl)-8-oxo-5-thia-1-azabicyclo[4,2,0]oct-2-ene-2-carboxylic acid (cefazedone, Refosporen), a new semisynthetic cephalosporin, was compared with that of cefazolin in two consecutive cross-over studies conducted on 10 healthy male volunteers each. The systemic tolerance of cefazedone after 1 X 500 mg and 1 X 1000 mg i.v., and 1 X 500 mg i.m. injections was very good and comparable with that of cefazolin. The same holds true for the local tolerance after i.v. administration. The local tolerance of i.m. administered cefazedone can also be classified as good when compared with that of cefazolin.
D000328:Adult; D002437:Cefazolin / Q000008:administration & dosage / Q000009:adverse effects*; D002511:Cephalosporins / Q000008:administration & dosage / Q000009:adverse effects*; D004341:Drug Evaluation; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged
D002511:Cephalosporins; D002437:Cefazolin